| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Report description
The Amgen Partnering Guide 2008 provides an in-depth insight into the
partnering interests and activites of one of the worlds leading biopharma
companies.
This report provides all the information you require to better understand
Amgen and its partnering interests and activities over the past five years.
One of the key aspects of partnering is finding those companies that are
potential partners for the development and commercialization of the next
generation of therapies as developed by innovative biopharma R&D companies. A
lot of resources are spent on finding partners, identifying their interests
and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently determine the
suitablility of Amgen as a prospective partner, their business development
objectives, interests and recent partnering activity, key partnering contacts,
and partnering contract documents signed with their recent partners.
The report provides a firm basis for initial due diligence into Amgen as a
prospective partner company.
The initial chapters of this report provide an orientation of bigpharma's
dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst Chapter
2 lists the top 50 leading biopharma companies based on 2007
pharmaceutical revenues. Chapter 3 analyses the most active dealmakers
between 2005 and 2007 in M&A and partnering deals announced, whilst Chapter
4 identifies the top deals of 2005-7 according to reported deal size.
Chapter 5 provides details on how to approach bigpharma companies with
partnering opportunities whilst Chapter 6 lists forthcoming partnering
events and conferences where bigpharma companies will be present to discuss
opportunities face to face.
Chapter 7 provides a series of matrices that summarize the company's
activity in terms of marketed and pipeline products, partnering interests and
partnering activity by therapeutic area.
The main body of the report is provided in Chapter 8. An in-depth
profile of the company provides everything required to assess the suitability
of a company as a prospective partner. This includes a company overview,
detailed analysis of the company's marketed and pipeline disease targets,
partnering interests, partnering activity according to deal type, phase of
development, therapy area. The profile also includes in-depth contact
information for individuals within the business development function.
The company profile is also provided with a comprehensive listing of contract
documents available in the public domain. The listing is sorted by deal type -
therefore co-promotion deals are listed separately to licensing, M&A and
supply deals, and so on.
Each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
In summary, the report provides the user with the tools to make successful
contact with the right bigpharma partners effectively and efficiently.
Key benefits
Amgen Partnering Guide 2008 report provides the user with the following key benefits:
- Detailed company profile of the company
- In-depth marketed and pipeline product activity for the company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 - number of deals per year
- Partnering activity for 2005-2008
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Comprehensive access to actual contracts entered into by the company and
its partners*
- Insight into the terms included in a partnering agreement
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
*Subject to being published via regulatory requirements of the Securities
Exchange Commission.
Report scope
Amgen Partnering Guide 2008 is intended to provide the reader with an
in-depth understanding of the partnering activities and interests of the
company, enabling the effective assessment and selection of partners of
choice, based on the latest knowledge of a company's approach to partnering.
Amgen Partnering Guide 2008 includes:
- Detailed company profile including:
- Full contact details
- Business developer contact details including name, title, email and
telephone (where available)
- Marketed indications
- Pipeline indications
- Partnering interests and indications
- Partnering activity since 2000
- Current partner companies since 2005
- Partnering activity since 2005 by:
- Deal type
- Stage of development
- Therapy area
- Numerous charts showing the dealmaking activity of the company since 2005
- The tools to enable effective and efficient preparation for partnering
negotiation with the company
- Listing of contract documents between the company and its partners
- The leading M&A and partnering deals by value 2005-8
- Most active M&A and partnering dealmakers 2005-8
The Amgen Partnering Guide 2008 report also provides comprehensive
access to available contract documents for the company.
Analyzing actual company agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subscontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Number of pages: The report is comprised of 53 pages.
TABLE OF CONTENTS
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Bigpharma - The Top 50
Chapter 3 - Most active bigpharma dealmakers
- 3.1 Bigpharma M&A activity
- 3.2 Bigpharma partnering
Chapter 4 - Top bigpharma deals - 2000-7
- 4.1 Bigpharma M&A
- 4.2 Bigpharma partnering
Chapter 5 - Submitting Opportunities to Bigpharma such as Amgen
- 5.1 How to submit an opportunity
- 5.2 Opportunity submission template
- 5.3 Sending emails
- 5.4 Face to face at partnering events
- 5.5 Online submission forms
Chapter 6 - Forthcoming bigpharma partnering events
Chapter 7 - Amgen - therapy locator
- 7.1 How to use the therapy matrix tables
- 7.2 Therapeutic area definitions
- 7.3 Amgen - Therapeutic target matrix - marketed and pipeline compounds
- 7.5 Amgen - Therapeutic target matrix - expressed partnering interests
- 7.6 Amgen - Therapeutic target matrix - recent deals - 2005-2007
Chapter 8 - Bigpharma Company Profiles
- 8.1 How to use company profiles
- 8.2 Field definitions
- 8.3 Amgen company profile
- Company contact details
- Subsidiary companies
- Primary therapy areas
- Business development contacts
- Company description
- Marketed therapeutic indications
- Pipeline (phase I-III) therapeutic indications
- Partnering interests
- Partnering interests - therapeutic indications
- Partnering frequency per annum - 2000-2008
- Current partner companies (2005-8)
- Recent deals 2005-2008
- By deal type
- By stage of development
- By therapy area
- Contract documents available online - link direct to each document
Figures in report
- Figure 1: Bigpharma - top 50 by pharma revenues 2007
- Figure 2: Leading Bigpharma M&A companies, 2005-7
- Figure 3: Leading Bigpharma partnering companies, 2005-7
- Figure 4: Leading M&A deals involving bigpharma by value, 2005-7
- Figure 5: Leading partnering deals by value, 2005-7
- Figure 6: Typical partnering opportunity submission template
- Figure 7: Partnering events 2008-9
- Figure 8: Therapeutic area definitions
- Figure 9: Therapeutic target matrix - marketed and pipeline compounds
- Figure 10: Therapeutic target matrix - expressed partnering interests
- Figure 11: Therapeutic target matrix - recent deals 2005-7
- Figure 12: Company profile template and definitions used in report
- Figure 13: Amgen - Dealmaking frequency 2000-2007
- Figure 14: Amgen - recent deals (2005-2008) by deal type
- Figure 15: Amgen - recent deals (2005 - 2008) by stage of development
- Figure 16: Amgen - recent deals (2005 - 2008) by therapy area
- Figure 17: Recent Amgen partnering deals (2003-2008) where contract
document available
- Figure 18: Online partnering resources
|
